The disappointing results of glucose lowering studies have highlighted the ongoing need to develop new therapeutic strategies to reduce cardiovascular risk in patients with type 2 diabetes. The presence of a range of metabolic abnormalities in diabetic patients presents a number of potential targets for therapeutic intervention. While modulation of peroxisome proliferator activated receptors (PPARs) represents an attractive approach, the results of studies of pharmacological agonists have been variable. The findings of these studies and rationale for development of dual PPAR-a/c agonists will be reviewed.
|Number of pages||6|
|Journal||Diabetes and Vascular Disease Research|
|Publication status||Published - 1 Apr 2012|
- Cardiovascular risk
- Clinical trials
- PPAR / agonists
- Therapeutic strategies